Category Archives: New York Stem Cells

Market Overview

Thecell culture media marketis expected to cross USD 4.33 billion by 2027 at a CAGR of8.33%.

Market Dynamics

The markets growth is being fueled by a diverse range of cell culture media applications, increased research and development in the pharmaceutical industry, an increase in the prevalence of chronic diseases, and increased expansion and product launches by major players. Over the last few decades, advancements in cell culture technology have accelerated. It is widely regarded as one of the most dependable, robust, and mature technologies for biotherapeutic product development.

The high cost of cell culture media and the risk of contamination, on the other hand, are impeding the markets growth. However, the growing emphasis on regenerative and personalized medicine is likely to spur growth in the global cell culture media market.

Get Sample Report: https://www.marketresearchfuture.com/sample_request/4462

Competitive Dynamics

The notable players are the Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), GE Healthcare (US), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), PromoCell (Germany), Sera Scandia A/S (Denmark), The Sartorius Group (Germany), and Fujifilm Holdings Corporation (Japan).

Segmental Analysis

The global market for cell culture media has been segmented according to product type, application, and end user.

The market has been segmented by product type into classical media, stem cell media, serum-free media, and others.

Further subcategories of stem cell culture media include bone marrow, embryonic stem cells, mesenchymal stem cells, and neural stem cells.

The market is segmented into four application segments: drug discovery and development, cancer research, genetic engineering, and tissue engineering and biochemistry.

The market is segmented by end user into biochemistry and pharmaceutical companies, research laboratories, academic institutions, and pathology laboratories.

Regional Overview

According to region, the global cell culture media market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas dominated the global cell culture media market. The large share is attributed to the presence of major manufacturers, rising disease prevalence resulting in increased demand for drugs and other medications, technological advancements in the preclinical and clinical segments, growing public awareness, and high disposable income.

Europe ranks second in terms of market size for cell culture media. Factors such as an increase in the biopharmaceutical sector in the European region, increased government initiatives to promote research to find a cure for the growing number of chronic diseases, an increase in the number of pharmaceutical manufacturers, improving economies, a high disposable income per individual, and increased healthcare spending are all contributing to the markets growth in this region. The European market is expected to be driven by expanding R&D activities and a developing biopharmaceutical sector.

Asia-Pacific held the third-largest market share, owing to the presence of numerous research organizations, low manufacturing costs, low labor costs, developing healthcare infrastructure, and increased investment by American and European market giants in Asian countries such as China and India.

The Middle East and Africa, with limited economic development and extremely low income, held the smallest market share in 2019 but is expected to grow due to growing public awareness and demand for improved healthcare facilities in countries, as well as rising disposable income.

Browse Full Reports: https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

Related Report: Dysmenorrhea Treatment Market Research Report- Global Forecast to 2027

Syringe and Needle Market Research Report Global Forecast to 2027

Global Medical Robotics Market Research Report- Forecast To 2027

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Here is the original post:
Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time.

MIAMI (PRWEB) July 26, 2022

The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, announced today that Shai Efrati, MD, the worlds foremost research scientist on hyperbaric oxygen therapy, will keynote at the conference being held at the Hilton Tel Aviv from October 31 to November 3. Efrati is a professor at Sackler School of Medicine and the Sagol School of Neuroscience at Tel Aviv University and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Centerthe largest hyperbaric center in the world, treating over 350 patients a day.

Efratis lab has created a unique approach for hyperbaric oxygen therapy (HBOT) which consists of immersing people in a high-pressure, high-oxygen environment and then carefully regulating oxygen and pressure levels. This technique, which is called the hyperoxic-hypoxic paradox (HHP), tricks the body into entering a regenerative state which unleashes a cascade of biological changes. These include the proliferation of stem cells, the generation of new blood vessels, and the repair of brain cells and tissue.

Eye-opening evidence:

Over the last decade, Efratis research team has authored dozens of high-quality clinical studies that show how this specific HBOT therapy revolving around the hyperoxic-hypoxic paradox has eye-opening impact on so many conditions. It can significantly boost brain function in stroke and traumatic brain injury patients, heal the wounds in the brain caused by PTSD, improve sexual function, and roll back the process of skin aging. This month, their randomized controlled trial found that the therapy incited brain healing and improved myriad symptoms in long Covid sufferers, an area where solutions have been elusive.

But its his recent research on healthy individuals that has such extraordinary implications for the wellness world. The therapy was recently shown to significantly improve (not just slow the loss of) cognitive function in healthy, older adults by generating new neurons and blood vessels in the brainthe first study to demonstrate that a brain can be made younger. Another recent study revealed that the treatment reversed two major processes associated with aging and its illnesses: the shortening of telomeres (the protective caps at the ends of every chromosome) and the accumulation of old, malfunctioning cells in the body. Participants telomeres were lengthened up to 38% while senescent cells saw a decrease of up to 37%.

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time. Its analogous to the first time that man landed on the moon. After that first landing, everyone wanted to travel there, but even faster and more effectively. So, well see young scientists rush to study aging and huge investment in this area, said Efrati. Aging isnt a bad thing; its the functional decline that is. As the wellness world knows well, many more people seek solutions that can make them fully potent and active every single year of their life. The future is high-performance aging, and Im excited to share my vision of that futureand the rising place of hyperbaric oxygen therapy in the medical-wellness worldwith the leaders that will gather at the Summit.

Caution: This isnt the hyperbaric oxygen treatment at your corner spa:

Hyperbaric oxygen treatments are spawning at spas and wellness centers and with at-home products. But, as Efrati cautions, its not even the same approach: these offerings simply involve putting people in a sack, or pod, full of minimally pressurized, oxygenated air, when thats not what makes HBOT effective. The game-changing component is the hyperoxic-hypoxic paradox: the precise protocols weve optimized for oxygen and pressure levels, fluctuations, and durations that spark the regenerative process in the body, said Efrati. This evidence-based therapy has to be performed in a medical facility by a trained physician. All these oxygen spas and pods can be dangerous: they miss the quality assurance of the air pump being inside, and they pose threats of oxygen toxicity and other health issues. Theyre also not effective. The future is clearing up much confusion in the marketplace about what evidence-based hyperbaric oxygen therapy actually entails and achieves.

Aviv Clinics: Rolling out this evidence-based treatment globally:

To make a more powerful global impact and to walk faster, Efrati co-founded AVIV Scientific, a research organization and network of global medical-wellness clinics focused on innovative applications of hyperbaric medicine using the HHP protocols, that can increase cognitive and physical performance in healthy aging adults. Clinics are open in Tel Aviv, at The Villages in central Florida, and most recently in Dubaiand are expected to come to New York and the UK soon. Aviv plans 50 clinics around the world within the next decade. Each clinic combines HBOT with personalized medicine, cognitive and fitness training, and nutrition coaching. Thanks to an exclusive partnership with the worlds largest hyperbaric research facility, the Sagol Center at Shamir Medical Center, each patient's data and samples are sent to the centers large research lab, where blood, DNA, telomeres, MRI results, etc. are analyzed. Since Sagol Center is doing so much research, positive findings can immediately be implemented at the clinics. For instance, with their new trial indicating that HBOT can help with long Covid damage to the brain, new programs were quickly rolled out.

Every year we aim to bring the brightest stars in health and wellness to the stage, and Dr. Efrati is exactly the kind of innovator we seek: a dynamic thinker whose work will really shake up our future, whose solutions are grounded in evidence, and who understands that new connections between medicine and wellness lie ahead, said Susie Ellis, GWS chair and CEO. Its an incredible opportunity for delegates to be immersed in his research on the future of aging at such an early, pivotal moment. What hes doing is game-changing.

Registration for the 2022 Summit is now open.

About the Global Wellness Summit The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor Reverse Pitch events and Global Wellness Symposiums. The organizations annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.

Share article on social media or email:

Continue reading here:
Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web

When Herminia Pasantes Ordez was about 14 years old, in 1950, she heard her mother tell her father that she would never find a husband. Pasantes had to wear thick glasses for her poor eyesight. In her mothers eyes, those glasses meant her future as a good woman was doomed. This made my life easier, says Pasantes, because it was already said that I was going to study.

At a time when it was uncommon for women to become scientists, Pasantes studied biology at the National Autonomous University of Mexico in Mexico City, or UNAM. She was the first member of her family to go to college.

Headlines and summaries of the latest Science News articles, delivered to your inbox

Thank you for signing up!

There was a problem signing you up.

She became a neurobiologist and one of the most important Mexican scientists of her time. Her studies on the role of the chemical taurine in the brain offer deep insights into how cells maintain their size essential to proper functioning. In 2001, she became the first woman to earn Mexicos National Prize for Sciences and Arts in the area of physical, mathematical and natural sciences.

We basically learned about cell volume regulation through the eyes and work of Herminia, says Alexander Mongin, a Belarusian neuroscientist at Albany Medical College in New York.

Pasantes did get married, in 1965 while doing her masters in biochemistry at UNAM. She had a daughter in 1966 and a son in 1967 before starting a Ph.D. in natural sciences in 1970 at the Center for Neurochemistry at the University of Strasbourg in France. There, she worked in the laboratory of Paul Mandel, a Polish pioneer in neurochemistry.

The lab was trying to find out everything there was to know about the retina, the layer of tissue at the back of the eye that is sensitive to light. Pasantes decided to test whether free amino acids, a group that arent incorporated into proteins, were present in the retinas and brain of mice. Her first chromatography a lab technique that lets scientists separate and identify the components of a sample showed an immense amount of taurine in both tissues. Taurine would drive the rest of her scientific career, including work in her own lab, which she started around 1975 at the Institute of Cellular Physiology at UNAM.

Taurine turns out to be widely distributed in animal tissues and has diverse biological functions, some of which were discovered by Pasantes. Her research found that taurine helps maintain cell volume in nerve cells, and that it protects brain, muscle, heart and retinal cells by preventing the death of stem cells, which give rise to all specialized cells in the body.

Contrary to what most scientists had believed at the time, taurine didnt work as a neurotransmitter sending messages between nerve cells. Pasantes demonstrated for the first time that it worked as an osmolyte in the brain. Osmolytes help maintain the size and integrity of cells by opening up channels in their membranes to get water in or out.

Pasantes says she spent many years looking for an answer for why there is so much taurine in the brain. When you ask nature a question, 80 to 90 percent of the time, it responds no, she says. But when it answers yes, its wonderful.

Pasantes lab was one of the big four labs that did groundbreaking work on cell volume regulation in the brain, says Mongin.

Her work and that of others proved taurine has a protective effect; its the reason the chemical is today sprinkled in the containers that carry organs for transplants. Pasantes work was the foundation for our understanding of how to prevent and treat brain edema, a condition where the brain swells due to excessive accumulation of fluid, from head trauma or reduced blood supply, for example. She and other experts also reviewed the role of taurine for Red Bull, which added the chemical to its formula because of potentially protective effects in the heart.

Pasantes stopped doing research in 2019 and spends her time talking and writing about science. She hopes her story speaks to women around the world who wish to be scientists: It is important to send the message that it is possible, she says.

Years before she was accepted into Mandels lab, her application to a Ph.D. in biochemistry at the UNAM was rejected. Pasantes says the reason was that she had just had her daughter. Looking back, this moment was one of the most wonderful things that couldve happened to me, Pasantes says, because she ended up in Strasbourg, where her potential as a researcher bloomed.

Rosa Mara Gonzlez Victoria, a social scientist at the Autonomous University of the State of Hidalgo in Pachuca, Mexico, who specializes in gender studies, recently interviewed Pasantes for a book about Mexican women in science. Gonzlez Victoria thinks Pasantes response to that early rejection speaks to the kind of person she is: A woman that takes those nos and turns them into yess.

See more here:
Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine

A JOURNALIST revealed the chilling clue that disclosed her lover and famed surgeon as a "romance scammer."

Documentary producer Benita Alexander thought it was love when her job introduced her to internationally renowned surgeon Paolo Macchiarini.

5

5

5

5

Benita was pursuing a big story when the ill-fated lovers met in 2013.

A successful TV journalist, the single mother-of-one was interviewing him for a report on cutting-edge medicine.

"I was doing a story about regenerative medicine and his name kept coming up," Benita, a New York resident, said on the podcast Dr Death: Miracle Man.

Macchiarini had been credited with developing innovative surgical techniques using stem cells in synthetic trachea transplants.

They became friends and over time she felt herself falling for him, despite her journalistic integrity impeding the romance.

"He seemed like he was the miracle man," she said.

"He was a top doctor, he spoke six or seven languages.

"He was a good listener and gave me sage and solid advice."

In mid-2013, they became a couple and in December that year they became pre-engaged as Macchiarini, who lived in Barcelona, Spain, said he was still legally married with two children but had been separated for a long time and was filing for divorce.

It was eight months later when they became properly engaged after Macchiarini presented her with a $100K ring.

The couple had the wedding planned for July 2015.

"The headline is that it started out as a beautiful love story and it ended up as a total nightmare," said Benita.

"I, to this day, have no idea why he lied about our entire relationship."

Macchiarini and Benita quickly started planning an extravagant wedding, she said.

It was beyond Benita's wildest dreams - Macchiarini reportedly told her he invited Bill Clinton, Barack Obama, and Elton John, and that the Pope himself would oversee the ceremony.

It was at this point that Benita said she started to feel that something was not right.

After doing some digging, it transpired that Macchiarini was not the medical genius she thought he was.

In fact, the scientist was embroiled in lawsuits and accusations at work.

"I went full on into investigator mode as I knew he wouldnt tell me the truth," Benita said.

She found out exactly what hed lied about - and she said it was extensive.

He had told her, as personal surgeon to the Pope, the leader of the Catholic church wanted to marry the couple, she explained.

"He said he was having trouble finding a priest to marry us," she said.

"Then he said he had connections to the Vatican. It wasnt surprising being a surgeon in Italy.

"He [the Pope] wanted to use us as the poster couple for the Catholic church, to prove people who are divorced can get married in the Catholic church."

But Benita's intuition overtook her and she hired a private investigator to look into the surreal wedding.

"None of these people were coming," Benita said she tragically discovered.

"He didnt know Pope Francis, he wasnt his personal doctor."

The slip from "Prince Charming to pathological liar" took place over just two years, she said.

In July 2015 their "cat and mouse game" came to an end when she revealed to him everything she found through the private investigation.

"I put it all in a message. He responded wow,'" Benita claimed.

Macchiarini ran into some legal trouble regarding his stem cell treatments with Swedish prosecutors recently appealing a sentence given to the Italian surgeon, the Associated Press reported.

He was put on trial after his patients reportedly suffered bodily harm during his experimental surgeries but he always denied any criminal wrongdoing.

ABC News reported that Macchiarini has never spoken publicly about his relationship with Benita.

Benita and Macchiarini's wild relationship was featured in a special episode of ABC's 20/20 on Friday.

5

Here is the original post:
Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun

Researchers in London found that male skin cancer deaths increased by 219% since 1973, compared to 76% for women in the same period. Meanwhile, a separate study found that Black and Latino cancer patients experienced more delays in care than white patients. Other research covers covid, menstruation, Alzheimer's, and more.

Fox News:Men's Skin Cancer Deaths Are Higher Than Women's: New AnalysisCancer Research UK an independent cancer research organization in London examined skin cancer fatality records.The group found that male melanoma skin cancer deaths have increased by 219% since 1973.(Moore, 7/17)

CIDRAP:Cancer Treatment Delays Spotlighted In Minority Groups Amid COVID-19A higher proportion of Black (75.6%) and Latino (80.2%) participants and those of other races (75.9%) experienced care modifications, including delayed clinic visits, lab tests, and imaging, as well as a change in care location than White participants (57.1%). A higher proportion of Black (98.0%) than White respondents (84.1%) who had care modifications said their clinic or physician requested the modifications. (7/15)

On covid research news

The New York Times:Covid-19 Vaccines Temporarily Changed Menstrual Cycles, Study ShowsNearly half of the participants of a recent study who were menstruating regularly at the time of the survey reported heavier bleeding during their periods after receiving the Covid-19 vaccine. Others who did not typically menstruate including transgender men, people on long-acting contraceptives, and post-menopausal women also experienced unusual bleeding. (Sheikh, 7/15)

CBS News:Studying The Effects Of Long COVIDSince contracting COVID-19 back in January 2021, Ken Todd has never made a full recovery, making him one of the millions who suffer from "long COVID." (7/17)

CIDRAP:More (Mostly Mild) Side Effects When Flu Vaccine Given With COVID BoosterSelf-reported data from nearly 1 million Americans show an 8% to 11% higher rate of mostly mild systemic adverse events after simultaneous seasonal flu vaccine and mRNA COVID-19 booster (third) doses than with the COVID-19 booster alone. (Van Beusekom, 7/15)

In news about other research

CIDRAP:Study Shows Global Rise In Macrolide-Resistant Mycoplasma PneumoniaeAntibiotic resistance, one of the most common causes of community-acquired pneumonia (CAP) in children, has risen dramatically over the past two decades, according to a study published this week in JAMA Network Open. To analyze global patterns, temporal trends, and regional variations in macrolide-resistant Mycoplasma pneumoniae (MRMP) infections, a team of South Korean researchers conducted a systematic review and meta-analysis of 153 studies from 150 articles published prior to Sep 10, 2021. (7/15)

Zenger News:Glass Of Wine A Day May Lead To Alzheimer's, Research SuggestsJust one small glass of wine a day could give you Alzheimer's or Parkinson's, according to new research. Consuming just seven units of alcohol a week - half the recommended maximum - fuels iron in the brain. (Kitanovska, 7/16)

AP:High-Flying Experiment: Do Stem Cells Grow Better In Space?Researcher Dhruv Sareens own stem cells are now orbiting the Earth. The mission? To test whether theyll grow better in zero gravity. Scientists at Cedars-Sinai Medical Center in Los Angeles are trying to find new ways to produce huge batches of a type of stem cell that can generate nearly any other type of cell in the body and potentially be used to make treatments for many diseases. The cells arrived over the weekend at the International Space Station on a supply ship. (Ungar, 7/17)

Also, in innovations

The Wall Street Journal:High-Tech Smell Sensors Aim To Sniff Out Disease, ExplosivesAnd Even MoodsBut now scientists and entrepreneurs are redoubling their efforts to recreate the sense of smell in compact devices that detect and analyze odors similar to the way cameras now recognize our faces and microphones our words. In pursuit of these high-tech deviceswhich could use odors to detect disease like cancer or Covid-19, locate hidden explosives or decipher our moods and behaviorssome companies are leveraging advances in synthetic biology and genetic engineering. Others are harnessing advances in artificial intelligence. (Hernandez, 7/16)

Reuters:Roche Launches Dual Antigen And Antibody Diagnostic Test For Hepatitis CRoche (ROG.S) has launched an new dual antigen and antibody diagnostic test for hepatitis C, the Swiss pharmaceuticals company said on Monday, which it says will give an earlier diagnosis of the virus. The Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus status from a single human plasma or serum sample. (7/18)

Read more:
Melanoma Kills Nearly Twice The Number Of Men Than Women: Study - Kaiser Health News

Desperate to have their lives back, long COVID patients are turning to an expensive last resort therapy to cure the mysterious illness.

Apheresis, or blood washing, is a process in which a component of blood, such as plasma, is separated and then filtered back into your body via giant needles inserted into a vein.

Gitte Boumeester, who found out about blood washing through a Facebook support group, spent more than $15,000 to have the treatment, BMJ and ITV News reported, in a joint investigation out Tuesday.

I thought, whats the worst thing Ive got to lose? the Dutch psychiatrist-in-training told reporters. Money was the only thing.

And that she did once Boumeester concluded, two months after the procedure, that the blood washing didnt work.

The process is typically used in cases where its necessary to remove specific components of blood, such as the treatment of blood cancers, plasma and platelet donation or to collect stem cells.

But in Germany, doctors consider it one of the last resorts for the treatment of some lipid disorders, which are marked by abnormal levels of lipids, or fats, in the blood the effects of which some have theorized are similar to long-term COVID infection.

Boumeesters battery of tests revealed nothing about her condition, which developed soon after she caught the SARS-CoV-2 virus in November 2020, despite her debilitating exhaustion.

Yet some researchers, namely Dr. Beate Jaeger, have hypothesized that long COVID may be caused by small clots in the blood that get in the way of the flow of oxygen, leading to the telltale extreme fatigue and muscle aches. Thus, washing the blood of unnecessary lipids and proteins, in combination with the use of anticoagulants, blood thinners such as clopidogrel, apixaban and heparin, could help clear the capillaries for better blood circulation.

Jaeger, a cardiovascular specialist in Mlheim, Germany, fought to see apheresis used on COVID patients in the ICU and to publish a paper on her approach, attempts of which were denied. Finally, a pair of her patients agreed to undergo the treatment free of charge. Then, 60 more opted-in. Shes since seen extremely successful results in thousands of patients, she said.

In one of her reports, Jaeger claimed that a long COVID patient who used a wheelchair could miraculously walk again following treatment. Another improved their stride from a labored walk to a jog.

Beverley Hunt, medical director of the charity Thrombosis UK, told BMJ, I am worried these patients have been offered therapies which have not been assessed by modern scientific methods: well-designed clinical trials. In this situation the treatment may or may not benefit them but, worryingly, also has the risk of harm.

The process of apheresis is safe if properly performed, but there are potentially dire consequences to having overly-thin blood, particularly if hemorrhage occurs.

Even under the safest conditions, patients also risk financial ruin. Boumeester traveled some 1,700 air miles to the Long Covid Center in Larnaca, Cyprus. For two months, she rented an apartment on the beach while making weekly appointments for apheresis, and more unproven add-on therapies, such as hyperbaric oxygen and intravenous vitamin infusions.

Six rounds of blood washing cost her more than $1,600 per session, while additional treatments came with price tags up to about $150, which she did on the recommendation of the clinicians.

I was a little ambivalent about all the extra treatment, but I promised myself if I was there I would do anything, to just try, she said.

Experimental treatments are generally permitted throughout Europe as long as theres clear patient consent, but experts fear that clinics like the Long Covid Center may be overpromising.

People could potentially go bankrupt accessing these treatments, for which there is limited to no evidence of effectiveness, said University of Birmingham researcher Shamil Haroon, whose work on the Therapies for Long Covid in Non-hospitalized Patients trial will eventually go on to inform how doctors approach the disease.

Like Boumeester, British businessman Chris Witham, from Bournemouth, traveled across the continent, toKempten, Germany, for a $7,000 course of apheresis that didnt work.

Id have sold my house and given it away to get better, without a second thought, he told BMJ and ITV News.

The outlets spoke to just six long COVID patients who said the procedure improved some of their condition, though symptoms lingered.

Their reporting flies in the face of claims made by Austrian entrepreneur and long COVID sufferer Markus Klotz, who founded the clinic in Cyprus and claims it worked for him after having the treatment with Jaegar in Mlheim. Over 80% of patients report to keep their gains permanently, read one post on the Facebook page for the Apheresis Association, also led by Klotz.

I realized before I started that the outcome was uncertain, but everyone at the clinic is so positive that you start to believe it too and get your hopes up, Boumeester said.

Read more here:
Patients have turned to pricey 'blood washing' to treat long COVID - New York Post

[250 Pages Report]As per a latest industry analysis by Future Market Insights, the global interferons market was valued at around US$ 9.1 Bn in 2021 and is anticipated to exhibit a CAGR of 3.9% over the forecast period (2022-2032).

A group of proteins produced by white blood cells, fibroblasts, and T-cells in response to viral infections, bacteria, tumor cells, and other pathogens are known as interferons. These glycoproteins, also known as cytokines, are frequently referred to as the first line of defense against pathogens.

Request Sample Copy of [emailprotected]https://www.futuremarketinsights.com/reports/sample/rep-gb-15158

Interferons have proved to be a cutting-edge and successful treatment option for illnesses such as cancer, hepatitis, and multiple sclerosis. In November 2021, for instance, the FDA approved BESREMi for the treatment of adults living with polycythemia vera, which is a recent advancement in the interferons industry.

Polycythemia vera is a group of rare, chronic, and life-threatening blood cancers caused by a mutation in bone marrow stem cells, which further leads to an abundance of blood cells. When this happens, a person is at high risk of significant health problems such as blood clots, strokes, and heart attacks.

One of the other factors driving the global interferons market is rising focus of key players on the development of innovative interferon-beta medications. Key players are also focusing on expanding their presence with the help of promotions, improved distribution networks, and enhanced customer services related to their products for the betterment of the brand and products.

For instance, in March 2020, Bayer and Curadev signed a research collaboration and license agreement to develop a novel stimulator of interferon genes (STING) antagonists across indications. It is known to help activate the innate immune system in auto-inflammatory diseases. Such breakthroughs in the global market are projected to bode well for the interferons industry in the upcoming decade.

Key Takeaways: Interferons Market

Ask from Market Research [emailprotected] https://www.futuremarketinsights.com/ask-question/rep-gb-15158

Growing number of therapeutic interferon approvals and their surging commercial applications in several disease indications are expected to propel the global interferons market, says an analyst of Future Market Insights.

Competitive Landscape: Interferons Market

Leading manufacturers such as Pfizer, Merck & Co., Zydus Cadila, and Novartis AG are focusing on collaborations and acquisitions to enhance their presence in the market and compete with their rivals during the forecast period. Below are some of the latest industry developments by key market participants:

More Valuable Insights on Interferons Market:

Future Market Insights brings a comprehensive research report on projected revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global interferons market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the interferons market segments based on product (interferon gamma, interferon beta, and interferon alpha), indication (multiple sclerosis, polycythemia vera, hepatitis C, melanoma, chronic granulomatous disease (CGD), and other indications), and end user (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies) across seven major regions.

For in-depth insights, Download a PDF [emailprotected] https://www.futuremarketinsights.com/reports/brochure/rep-gb-15158

Interferons Market Outlook by Category

By Product:

By Indication:

By End User:

Explore Other Reports Links From Healthcare Market

3D Bio Printing Market to grow at 12.9% CAGR through 2030 | Report by FMI

Intraosseous Infusion Devices Market Key Players : Pyng medical Corp., Aero Healthcare, Cook Medical Incorporated, PerSys Medical

Ophthalmic Lasers Market is estimated to increase from a valuation of US$ 884.3 Million in 2022

Proteinase K Market is projected to reach US$ 33.4 Million by the end of 2026

Organoids Market Key Players : Cellesce Ltd, DefiniGEN, Qgel, Hubrecht Organoid Technology (HUB), OcellO B.V.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:[emailprotected]uturemarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

The post Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 appeared first on Future Market Insights.

Read the original post:
Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 - Digital Journal

HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. ( AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria. The data demonstrate the cytotoxic potential of the CD123/CD16A-targeting bispecific innate cell engager (ICE) AFM28 which is in development as a novel treatment for patients with myeloid diseases, e. g. relapsed/refractory (R/R) acute myeloid leukemia (AML). AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo.

It is widely acknowledged that targeting CD123 holds significant untapped promise in developing better AML therapies. We believe our differentiated approach in targeting CD123 has the potential to provide a novel, innate immune system-engaging therapy to improve clinical outcomes, said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed. Following these encouraging pre-clinical proof-of-concept data and the experience we have gained from our AFM13 studies so far, we will be launching a first-in-human clinical study to investigate the compounds safety, efficacy and biological activity as monotherapy later this year and in combination with adoptive NK cells soon after.

The data presented at EHA today provide validation of the mechanism of action (MoA) as well as preclinical proof-of-concept for AFM28 in a range of in vitro and in vivo assays. AFM28 exhibited high-affinity binding to CD16A expressed on NK cells and high avidity conferring long cell surface retention in comparison to Fc-enhanced anti-CD123 antibody. Moreover, AFM28 demonstrated the ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity (ADCC).

Importantly, AFM28 was active irrespective of mutational status of tumor cells and also induced depletion when CD123 expression was very low. Strikingly, AFM28 was also active against cells not killed by an Fc-enhanced CD123-targeting comparator antibody suggesting the potential for improved clinical effectiveness. Moreover, AFM28 also depleted leukemic cells from patient bone marrow without destroying CD34-positive/CD123-negative cells, suggesting sparing of hematopoietic stem and progenitor cells.

In vivo studies in an AML murine model demonstrated anti-tumor efficacy, and cynomolgus toxicology models predicted pharmacodynamic activity with a well-tolerated safety profile and low risk of cytokine release syndrome.

Efficient depletion of leukemic blasts and leukemic stem cells is critical for inducing long-term remission in AML patients. As both cell types express CD123, AFM28s ability to redirect NK cells to this target killing both leukemic blasts and leukemic stem cells makes this an attractive treatment strategy. Currently, there are no curative immunotherapies available, the only option is allogenic hematopoietic stem cell transplantation (allo-HSCT).

Affimed plans to initiate clinical development of AFM28 with a first-in-human phase 1 monotherapy trial in adult patients with R/R AML in the second half of 2022. In addition, Affimed plans to investigate AFM28 in combination with allogeneic NK cell therapy after a safe starting dose has been determined.

The full poster is accessible through the following link: Publications and Posters - Affimed

Poster details:

Title: Novel bispecific innate cell engager AFM28 for the treatment of CD123-positive acute myeloid leukemia and myelodysplastic syndrome

Authors: Jana-Julia Siegler, Nanni Schmitt, Jens Pahl, Torsten Haneke, Izabela Kozlowska, Sverine Sarlang, Alexandra Beck, Stefan Knackmuss, Paulien Ravenstijn, Uwe Reusch, Jos Medina-Echeverz, Jan Endell, Thorsten Ross, Daniel Nowak, and Christian Merz

Final abstract code: P482

Session date and time: Poster session on Friday, June 10th, 10:30 11:45 a.m. EDT / 16:30 - 17:45 CEST

About AFM28

AFM28, a tetravalent, bispecific CD123- and CD16A-binding ICE developed on Affimeds ROCK platform, is designed to bring a new immunotherapeutic treatment to patients with CD123+ myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It engages NK cells to initiate tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC), even at low CD123 expression levels. Clinical development is planned as both monotherapy and in combination with allogeneic NK cells in patients with relapsed/refractory CD123-positive leukemias.

About Affimed N.V.

Affimed ( AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Companys proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the Companys people, pipeline and partners, please visit: http://www.affimed.com.

Investor Relations Contact

Alexander FudukidisDirector, Investor RelationsE-Mail: [emailprotected]Tel.: +1 (917) 436-8102

Media Contact

Mary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: [emailprotected] Tel.: +1 (484) 888-8195

Read the original here:
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) -...

Returning home after a Fathers Day trip to New York City with his daughter in 2016, Scott Kesel thought he had come down with the flu. Bloodwork showed his blood platelets were lower than normal. He followed up with his regular physician and was given the news: he had chronic myelomonocytic leukemia (CMML).

CMML is a rare type of blood cancer that starts in the bone marrow, where blood cells are made. It can involve other areas of the body. There are only about 1,100 cases in the U.S. each year and its more common in people over age 60.

As a Canandaigua resident, Scott started his cancer journey at Wilmot Cancer Institutes Sands Cancer Center at F.F. Thompson. His oncologist laid out all the options: chemo and a stem cell transplant.

Knowing he would need a transplant, his team at Sands had him transfer to Wilmots Hematology team, where he began seeing Jason Mendler, M.D., and his transplant doctor, Omar Aljitawi, M.B.B.S.

He had chemotherapy at Wilmot, where he got to know the infusion nursing staff.

They have put a mindset in place thats so beneficial to the patient, he says.

For a stem cell transplant, his brother was the closest match they could find, although he was only a half-match. That left the option for a haplo-identical transplant available. Historically, it was required to have a closer match in order to do a transplant. With a haploidentical transplant, the donor is only half-matched. Its a newer procedure that is not available at all transplant centers, but the doctors at Wilmot have been performing the surgery since 2015.

He underwent the transplant but, unfortunately, in Scotts case, it didnt work.

For a short period, Scott went to another institution for a clinical trial. Unfortunately, that didnt work either. He developed pancreatitis and had to drop out of the trial. He also experienced cold agglutinin disease, which caused his immune system to attack his red blood cells. Cold temperatures can trigger it and he had to stay at Wilmot for about a month in a temperature-controlled room, set at 80 degrees at all times, to overcome it.

Once that resolved, the team at Wilmot suggested another treatment option to try on Scotts leukemia: a transplant with stem cells from an umbilical cord donation. Umbilical cord blood stem cells came from Australia and Spain to try to save Scotts life. He had only two cord blood units available and he needed both to have a successful transplant, which was his only viable chance to potentially cure his leukemia. Along with the cord blood, he also had radiation therapy with Louis Constine, M.D.

He had nothing but good things to say about the team that took care of him while he was hospitalized on Wilmot Cancer Centers sixth floor, the Blood and Marrow Transplant Unit.

It was exceptional. They were so friendly and accommodating right from the very beginning, he says. It wasnt limited to nurses. Theres medical technicians on the floor that were so friendly and became very good friends.

Scott Kesel (right) with Jason Mendler, M.D., at the 2019 Wilmot Warrior Walk

Thankfully, this time the transplant took. As of June 2022, Scott has been in remission for three-and-a-half years. He credits his team for getting him there.

Its an incredible group of people, he says.

But its not just his team hes grateful for. He appreciates that his life has returned basically back to normal, despite the tumultuous COVID pandemic that happened shortly after his transplant.

Hes gotten back to work and to hobbies he enjoys outside work.

I happen to be the worlds greatest tuba playing car salesman, he jokes.

This summer and fall, he has 28 gigs lined up, with different music groups around the region to keep him busy, and he looks forward to hunting and fishing during his free time.

For it all, he feels fortunate.

You have to be grateful for the outcome, he says. I got a lot of support remotely from people in my community who used the opportunity to promote bone marrow registration and blood drives, which was awful nice.

He adds, Im grateful that I ended up at Wilmot. I really couldnt have been in a better place.

See the original post:
'World's Greatest Tuba-Playing Car Salesman' Bounces Back after Leukemia, Thanks to Wilmot Team - URMC

Professor Michael Hadjiargyrou, Ph.D., chair of the Department of Biological and Chemical Sciences and director of the D.O./Ph.D. program, has been named New York Institute of Technologys first distinguished professor. This designation is found at most top research universities and recognizes outstanding faculty who have achieved the highest levels of scholarship over the course of their careers, earning national- and international-level distinctions and honors of the highest caliber.

Interim Provost Jerry Balentine, D.O., and I were 100 percent in agreement that Professor Hadjiargyrou should be the first at New York Tech to receive this designation, notes New York Tech President Hank Foley, Ph.D. We have some very impressive faculty researchers, and he is absolutely one of the best. He is instilling his passion for research in our students while conducting important work in our labs in a variety of areas.

Foley pointed to the range of Hadjiargyrous work, which includes studying polymeric electrospun nanofibers for cell/gene/drug delivery systems, gene and miRNA (microRNA) expression, stem cells, and the molecular and cellular basis for bone development and regeneration, and the exciting implications his research has for future applications, such as gene delivery and treatment of difficult fractures.

According to his Google Scholar profile, Hadjiargyrou has an h-index (a measure research impact based on the total number of his publications and citations) of 37, one of the highest of any New York Tech researcher and considered to be outstanding in the greater research community. Between 1998 and 2022, his published research has been cited 7,711 times. In addition to his scientific research, Hadjiargyrou has also published thought leadership and opinion pieces on topics ranging from scientific integrity to teaching practices.

I am humbled by being named distinguished professor, and I will continue to live up to the title, says Hadjiargyrou. I would like to deeply thank President Foley and Interim Provost Balentine, not only for bestowing this award, but more importantly, for their continual support of my research activities.

Hadjiargyrou, who joined New York Tech in 2012, has been responsible for reinvigorating the Department of Biological and Chemical Sciences, including enriching the curriculum and support for research activities; hiring talented, engaged faculty researchers; and establishing the D.O./Ph.D. program in medical and biological sciences. During his tenure, he has worked to expand the number of undergraduate research opportunities, which has become the hallmark of a New York Tech education.

The creation of a distinguished professorship at New York Tech supports our goals of becoming a [Carnegie-classified] Research 2 university within the next seven years, says Foley, pointing to the universitys other investments in research activities, including adding new instrumentation and resources, new graduate programs, and hiring new research faculty.

Every two to three years, the distinguished professorship role and criteria will be reviewed by the president and provost, and new candidates will be considered for the designation.

Read the original:
Hadjiargyrou Is New York Tech's First Distinguished Professor | Box | New York Tech - New York Institute of Technology